Format

Send to

Choose Destination
Trends Mol Med. 2012 Jul;18(7):377-84. doi: 10.1016/j.molmed.2012.04.009. Epub 2012 May 19.

CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.

Author information

1
Clinical and Experimental Immunotherapy Group, School of Cancer and Enabling Sciences, The University of Manchester, Withington, Manchester M20 4BX, UK. dgilham@picr.man.ac.uk

Abstract

Recent reports on the impressive efficacy of adoptively transferred T cells to challenge cancer in early phase clinical trials have significantly raised the profile of T cell therapy. Concomitantly, general expectations are also raised by these reports, with the natural aspiration to deliver this therapy over a wide range of tumor indications. Chimeric antigen receptors (CARs) endow T cell populations with defined antigen specificities that function independently of the natural T cell receptor and permit targeting of T cells towards virtually any tumor. Here, we review the current clinical application of CAR-T cells and relate clinical efficacy and safety of CAR-T cell trials to parameters considered critical for CAR engineering, classified as the three T's of CAR-T cell manipulation.

PMID:
22613370
DOI:
10.1016/j.molmed.2012.04.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center